Abilify Asimtufii (Aripiprazole) Patent Expiration, LOE Window & CMS Spending

Abilify Asimtufii (Aripiprazole) by Otsuka Pharmaceutical: FDA Orange Book LOE 2033-04-23, 18 AB generics, $175.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOtsuka Pharmaceutical
FDA Application & PathwayN217006 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-04-23
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$175.6M
2024 Medicare Part D Spend$63.1M
2024 Medicaid Spend$112.5M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 3.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.